Gouvernement du CanadaAgence de santé publique du Canada / Public Health Agency of Canada
   
Sauter toute navigation -touch directe z Sauter au menu vertical -touch directe x Sauter au menu principal -touch directe m  
English Contactez-nous Aide Recherche Site du Canada
Accueil - ASPC Centres Publications Lignes directrices Index A-Z
Santé - enfants Santé - adultes Santé - aînés Surveillance Santé Canada
   
    Agence de santé publique du Canada
Relevé des maladies transmissibles au Canada

Conférence de concertation sur la coqueluche

[Table des Matières]

  

RÉFÉRENCES 

  1. CDC. Pertussis - United States, 1997-2000. MMWR 2002;51:76-6. 

  2. Wortis N, Strebel PM, Wharton M et coll.
    B. pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics 1996;97:607-12. 

  3. Heininger U, Stehr K, Schmidt-Schläpfer G et coll. Bordetella pertussis infections and sudden unexpected deaths in children. Eur J Pediatr 1996;155:551-53. 

  4. Jenkinson D. Natural course of 500 consecutive cases of whooping cough: a general practice population.Br Med J 1995;310:299-302. 

  5. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10-year community study. Br Med J 1988;296:612-14. 

  6. Yih WK, Lett SM, des Vignes FN et coll. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis 2000;182:1409-16. 

  7. Heininger U, Schmidt-Schläpfer G, Cherry JD et coll. Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial. Pediatrics 2000;105:31. 

  8. Senzilet LD, Halperin SA, Spika JS et coll. et le Groupe de travail sur la coqueluche du Système de surveillance par unité de santé sentinelle. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001;32:1691-97. 

  9. Decker MD, Edwards KM. The multicenter acellular pertussis trial: an overview. J Infect Dis 1996;174(suppl 3):S270-5. 

  10. Grimprel E, Guiso N, Bégué P. New aspects of pertussis in France, 26 years after generalized pertussis vaccination. Biologicals 1993;21:5-6. 

  11. Baron S, Njamkep E, Grimprel E et coll. Epidemiology of pertussis in France, 1993-1994. Pediatr Infect Dis J 1997;17:412-18. 

  12. Gilbert S, Njamkepo E, Parent du Châtelet I et coll. Evidence of Bordetella pertussis with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis 2002.186 (sous presse). 

  13. Miller E, Fleming DM, Ashworth LAE et coll. Serological evidence of pertussis in patients presenting with cough in general practice in Birmingham. Commun Dis Public Health 2000;3:132-4. 

  14. Crowcroft NS, Spicer L, Tzivra O et coll. Pertussis is under-estimated in infants admitted to paediatric intensive care units and wards in London (résumé). Proceedings of the 19th Annual Meeting of the European Society for Paediatric Infectious Diseases, Istanbul, Turkey, 2001. 

  15. Morris A, McIntyre P, Elliot E et coll. Hospitalised pertussis in Australian infants in 2001(résumé). Royal Australian College of Physicians Annual Scientific Meeting, Brisbane, Australia, May 2002. 

  16. Thomas P, McInytre P, Jalaludin B. Survey of pertussis morbidity in adults in western Sydney. Med J Aust 2000;173:74-76. 

  17. Poynton M, Irwig L, Hanlon M et coll. Serological diagnosis of pertussis: evaluation of IgA against whole cell and specific Bordetella pertussis antigens as markers of recent infection. Epidemiol Infect 2002 (in press). 

  18. Zepp F, Knuf M, Habermehl P et coll. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 1996;64:4078-84 

  19. Zepp F, Knuf M, Habermehl P et coll. Cell-mediated immunity after pertussis vaccination and after natural infection. Dev Biol Stand 1997;89:307-14. 

  20. Tinnion ON, Hanlon M. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2000;(2):CD001478. 

  21. Taranger J, Trollfors B, Bergfors E et coll. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics 2001;108 .
    URL :  http://www.pediatrics.org/cgi/content/full/108/6/e115 

  22. Salmaso S, Mastrantonio P, Tozzi AE et coll. Sustained efficacy during first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001;108(5):e81. 

  23. Lugauer S, Heininger U, Cherry JD et coll. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell component vaccine. Eur J Pediatr 2002;161:142-6. 

  24. Halperin SA, Eastwood BJ, Barreto L et coll. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine 1996;14:767-72. 

  25. Halperin S, Scheifele D, Barreto L et coll. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J 1999;18:772-79. 

  26. Pichichero ME, Edwards KM, Anderson EL et coll. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year old children. Pediatrics 2000;105:e11. 

  27. Schmitt HJ, Beutel K, Schuind A. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at 14 to 28 months of age. J Pediatr 1997;130:616-23. 

  28. Halperin SA, Smith B, Russell M et coll. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000;18:1312-19. 

  29. Hemels MEH et coll. Economic evaluation of an extended acellular pertussis programme for adolescents in Ontario, Canada. Devant être publié. 

  30. Comité consultatif national de l'immunisation, Comité consultatif de l'épidémiologie, Société canadianne de pédiatrie. Déclaration concernant la prise en charge des personnes exposées à la coqueluche et la lutte contre les épidémies de coqueluche. RMTC 1994;20(22):193-200. 

  31. Comité consultatif national de l'immunisation. Guide canadien d'immunisation, 4e éd. Ottawa: Association médicale canadienne, 1998. 

  32. Halperin S, Bortolussi R, Langley JM et coll. Seven days of erythromycin is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics 1997;100:65-71. 

  33. Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001;20:1149-54. 

  34. Halperin S, Bortolussi R, Langley JM et coll. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics 1999;104 .
    URL : http://www.pediatrics.org/cgi/content/full/104/4/e42 

  35. De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 1995;14:969-975. 

  36. Deeks S, De Serres G, Boulianne N et coll. Failure of physicians to consider the diagnosis of pertussis in children. Clin Infect Dis 1999;28:840-46. 

[Précédent] [Table des matières] [Prochaine]
Dernière mise à jour : 2003-06-05 début
Avis importants